PIEZO1 and lymphedema: Patients affected by lymphedema caused by mutations in PIEZO1 could benefit in future of therapy by Yoda1, a novel small synthetic molecule specific activator of PIEZO1 (Cahalan et al., 2015; Lacroix et al., 2018), or by gene therapy by selective insertion of the gene in the lymphatic system, or by in vivo target gene activation via CRISPR/CAS9 mediated trans-epigenetic modulation.